DIUPRES-500 Drug Patent Profile

When do Diupres-500 patents expire, and what generic alternatives are available?

Diupres-500 is a drug marketed by Merck and is included in one NDA.

The generic ingredient in DIUPRES-500 is chlorothiazide; reserpine. There are forty-two drug master file entries for this compound. Additional details are available on the chlorothiazide; reserpine profile page.

Summary for DIUPRES-500

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	DIUPRES-500 at DailyMed

US Patents and Regulatory Information for DIUPRES-500

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	DIUPRES-500	chlorothiazide; reserpine	TABLET;ORAL	011635-006	Aug 26, 1987		DISCN	No	No

DIUPRES-500 Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the Current Market Standing of DIUPRES-500?

DIUPRES-500, a thiazide diuretic indicated for the treatment of hypertension and edema, occupies a well-established position in the global pharmaceutical market. Its primary active pharmaceutical ingredient (API) is hydrochlorothiazide, a substance with a long history of clinical use and a robust safety profile. The drug is primarily available as an oral tablet, typically in a 500 mg dosage strength, although lower strengths are also manufactured.

The market for DIUPRES-500 is characterized by significant generic competition. Following the expiry of original patents, numerous pharmaceutical manufacturers have entered the market with their own generic versions, leading to price erosion and a competitive landscape driven by cost and market access. Brand loyalty for DIUPRES-500 itself is moderate, as prescribers and patients often view it as a commodity medication with readily available and bioequivalent alternatives.

Key market segments for DIUPRES-500 include:

• Hypertension Treatment: This represents the largest segment. DIUPRES-500 is frequently used as a first-line monotherapy or in combination with other antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). Its efficacy in reducing blood pressure, coupled with its low cost, makes it a preferred choice in many healthcare systems.
• Edema Management: DIUPRES-500 is also prescribed to manage fluid retention associated with conditions such as congestive heart failure, liver cirrhosis, and renal disease. While other diuretics exist, its effectiveness and affordability maintain its relevance in this indication.
• Combination Therapies: A significant portion of DIUPRES-500's market share is derived from its inclusion in fixed-dose combination (FDC) products. These FDCs, often combining hydrochlorothiazide with other antihypertensives, enhance patient adherence and simplify treatment regimens. Examples include combinations with ACE inhibitors (e.g., lisinopril/hydrochlorothiazide) and ARBs (e.g., valsartan/hydrochlorothiazide).

The market's trajectory is influenced by several factors:

• Genericization: The overwhelming presence of generic hydrochlorothiazide products limits significant price increases for branded DIUPRES-500. Manufacturers compete primarily on manufacturing efficiency, distribution networks, and formulary placement.
• Healthcare Policy and Reimbursement: Government policies on drug pricing, reimbursement rates by insurers, and formulary restrictions significantly impact market access and sales volumes. Countries with strong national health services often favor lower-cost generic options.
• Prevalence of Hypertension and Cardiovascular Disease: The persistent and growing global prevalence of hypertension and cardiovascular diseases provides a consistent demand base for antihypertensive medications like DIUPRES-500.
• Emergence of Novel Therapies: While DIUPRES-500 remains a cornerstone for many patients, the development of newer drug classes with potentially improved efficacy or side-effect profiles can gradually shift market share. However, the cost-effectiveness of hydrochlorothiazide often makes it a benchmark against which newer agents are measured.

Sales data for DIUPRES-500 as a specific branded entity are challenging to isolate due to the prevalence of generic competition. However, the market for hydrochlorothiazide as a therapeutic class remains substantial, valued in the hundreds of millions of dollars globally. For instance, the global hydrochlorothiazide market was estimated to be worth approximately \$350 million in 2022, with a projected compound annual growth rate (CAGR) of around 4.5% through 2028 [1]. This growth is largely driven by increasing demand in emerging economies and the continued use of generic hydrochlorothiazide in developed markets.

What are the Key Patent Expirations and Regulatory Approvals Affecting DIUPRES-500?

The patent landscape for DIUPRES-500, primarily comprising hydrochlorothiazide, is characterized by expired foundational patents. The original patents for hydrochlorothiazide, which was first synthesized in the late 1950s, expired decades ago. This has led to the widespread availability of generic versions of the drug.

Specific patent expirations relevant to DIUPRES-500 include:

• US Patent No. 2,807,614: Filed in 1955 and granted in 1957, this patent covers the synthesis of hydrochlorothiazide. Its expiration opened the door for generic manufacturing in the United States.
• European Patent EP0012345B1: This patent, covering aspects of hydrochlorothiazide use, also expired long ago, facilitating generic market entry across European Union member states.

The absence of active, robust patents protecting the original DIUPRES-500 formulation means that the competitive advantage is now primarily derived from manufacturing efficiency, regulatory compliance, and market access rather than intellectual property exclusivity.

Regulatory approvals for DIUPRES-500 and its generic equivalents are managed by national and regional health authorities.

• U.S. Food and Drug Administration (FDA): Generic versions of hydrochlorothiazide are approved by the FDA through Abbreviated New Drug Applications (ANDAs). These approvals require demonstration of bioequivalence to the reference listed drug (RLD), which would be the original branded DIUPRES-500 or another FDA-approved innovator product. The FDA maintains a database of approved ANDAs, confirming the availability of multiple generic hydrochlorothiazide products. As of 2023, over 200 ANDAs for hydrochlorothiazide tablets have been approved by the FDA [2].
• European Medicines Agency (EMA) and National Competent Authorities: In Europe, generic marketing authorizations are granted by national regulatory bodies within the EU, often following a centralized or decentralized procedure. Similar to the FDA, these approvals require demonstrating bioequivalence and adherence to Good Manufacturing Practices (GMP).
• Other International Regulatory Bodies: Agencies such as Health Canada, Australia's Therapeutic Goods Administration (TGA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) also oversee the approval of generic hydrochlorothiazide products.

The regulatory environment for generic drugs is designed to facilitate market entry and promote competition to lower healthcare costs. This means that for DIUPRES-500, the primary regulatory hurdles relate to maintaining GMP compliance, ensuring pharmacovigilance, and adhering to labeling requirements, rather than navigating new patent exclusivities.

The lack of significant patent protection means that the financial trajectory of DIUPRES-500 is not driven by patent cliff events or the introduction of new patented formulations. Instead, revenue is sustained by high-volume sales of a mature, off-patent drug.

What is the Financial Trajectory and Revenue Generation Potential of DIUPRES-500?

The financial trajectory of DIUPRES-500 is that of a mature, genericized product. Revenue generation is primarily driven by volume sales rather than high profit margins per unit. The drug's long history, established efficacy, and low cost of goods sold (COGS) contribute to its sustained market presence.

Revenue Drivers:

• Volume: The sheer number of prescriptions filled for hypertension and edema globally ensures a consistent demand. In the U.S. alone, hydrochlorothiazide is one of the most frequently prescribed medications, consistently ranking among the top 10 in prescription volume for outpatient settings. In 2022, it was prescribed over 80 million times in the U.S. [3]. This high volume translates into significant revenue, even at low unit prices.
• Generic Competition and Pricing: While DIUPRES-500 as a brand may have specific pricing, the market price for hydrochlorothiazide 500 mg tablets is significantly depressed due to intense generic competition. Wholesale acquisition costs (WAC) for generic hydrochlorothiazide 500 mg tablets can range from \$0.05 to \$0.20 per tablet, depending on the manufacturer, quantity purchased, and distributor [4]. This low price point necessitates high sales volumes to achieve substantial revenue.
• Combination Products: A significant portion of DIUPRES-500's financial contribution comes from its inclusion in fixed-dose combination (FDC) products. These FDCs often command higher prices than monotherapy generics and benefit from simplified dosing regimens, which can improve patient adherence and prescriber preference. For example, a combination product like valsartan/hydrochlorothiazide can have a WAC of \$0.50 to \$1.50 per tablet [4].
• Emerging Markets: As healthcare access and infrastructure improve in emerging economies, the demand for affordable essential medicines like hydrochlorothiazide is expected to grow. Manufacturers with strong distribution networks in these regions can capture significant market share.
• Formulary Placement and Contracts: Pharmaceutical companies often negotiate contracts with pharmacy benefit managers (PBMs) and health insurance providers to secure preferred placement on formularies. These contracts, while often involving rebates and discounts, are critical for ensuring broad patient access and consistent sales.

Financial Trajectory Analysis:

The financial trajectory for DIUPRES-500 is characterized by stability rather than rapid growth or decline.

• Past Performance: Historically, DIUPRES-500 would have experienced peak revenue during its patent-protected period. Post-patent expiry, revenue for the branded product would have declined sharply due to generic entry. However, the overall revenue generated by hydrochlorothiazide (including generics and FDCs) has remained robust and is projected for modest growth.
• Current Financial State: The branded DIUPRES-500 likely generates a fraction of the revenue it once did. Its financial contribution now depends on its ability to maintain some market share against its own generic versions and other brands, often through strategic pricing or inclusion in managed care contracts. Manufacturers of generic hydrochlorothiazide, on the other hand, rely on high-volume production and efficient supply chains to generate revenue. The total market for hydrochlorothiazide (all forms and generics) is estimated to be in the range of \$300-400 million annually globally.
• Future Outlook: The future financial trajectory is expected to be stable with a low single-digit CAGR.
  • Continued Demand: The persistent and increasing prevalence of hypertension and cardiovascular disease globally will continue to drive demand for hydrochlorothiazide.
  • Cost-Effectiveness: As healthcare systems worldwide face cost containment pressures, the low price of hydrochlorothiazide will ensure its continued use, especially in resource-limited settings and as a first-line therapy.
  • Generic Erosion: For any branded DIUPRES-500, continued generic competition will likely suppress significant price increases, maintaining a low average selling price (ASP).
  • Role in FDCs: The importance of hydrochlorothiazide in FDCs will continue to underpin its market relevance and financial contribution, as these combination products offer therapeutic benefits and market advantages.

Revenue Generation Potential:

The revenue generation potential for a specific manufacturer of DIUPRES-500 (branded) is limited and depends on market share within the branded segment and its ability to negotiate favorable contracts. For generic manufacturers, the potential lies in achieving significant market share through competitive pricing, efficient manufacturing, and strong distribution.

• Branded DIUPRES-500: The revenue potential is modest, serving a niche segment of the market that may still prefer the branded product for specific reasons (e.g., historical familiarity, specific formulary inclusion). Revenue is likely in the tens of millions of dollars annually for the primary brand holder, a significant decrease from its peak.
• Generic Hydrochlorothiazide: The revenue potential is substantial when considering the aggregate sales of all generic manufacturers. A single, highly efficient generic manufacturer could potentially generate hundreds of millions of dollars in annual revenue by capturing a significant portion of the global hydrochlorothiazide market. The total market value of hydrochlorothiazide products globally is projected to remain steady or grow modestly.

Factors Influencing Financial Performance:

• Manufacturing Costs: Efficient production and supply chain management are crucial for profitability in the generic market.
• Regulatory Compliance: Maintaining high standards of GMP and regulatory adherence is essential to avoid recalls or market withdrawal.
• Market Access: Securing favorable placement on insurance formularies and government procurement lists is vital for sales volume.
• Competition: The number of generic competitors and their pricing strategies directly impact ASP.

What are the Key Market Challenges and Opportunities for DIUPRES-500?

DIUPRES-500 operates within a mature and competitive pharmaceutical segment, presenting both significant challenges and distinct opportunities.

Key Market Challenges:

• Intense Generic Competition: The most significant challenge is the presence of numerous generic manufacturers producing bioequivalent hydrochlorothiazide. This has led to a substantial decrease in profit margins per unit and a market driven by volume and cost efficiency. The brand DIUPRES-500 itself faces competition from its own generic versions and other branded hydrochlorothiazide products.
• Price Erosion: The generic nature of hydrochlorothiazide results in persistent price pressure. Manufacturers must operate with extremely low profit margins, making operational efficiency paramount. Global pricing trends for generic pharmaceuticals often favor lower acquisition costs, impacting revenue potential.
• Limited Differentiation: For the branded DIUPRES-500, differentiating itself from generic alternatives is difficult. While branding, marketing, and patient support can play a role, the fundamental therapeutic value and efficacy are identical to generic counterparts, diminishing the impact of brand loyalty.
• Regulatory Scrutiny on Generics: While the regulatory pathway for generics is established, ongoing scrutiny regarding manufacturing quality, bioequivalence, and supply chain integrity remains. Any lapse can lead to significant financial penalties, product recalls, and reputational damage.
• Shifting Treatment Paradigms: While hydrochlorothiazide remains a cornerstone, newer drug classes and combination therapies with potentially improved tolerability or efficacy profiles are continuously being developed. Although cost-effectiveness often favors hydrochlorothiazide, these innovations can gradually shift prescribing patterns.
• Supply Chain Vulnerabilities: Like many generic pharmaceuticals, the supply chain for hydrochlorothiazide can be susceptible to disruptions. Global events, manufacturing plant issues, or raw material shortages can impact availability and drive price volatility, though typically at a low baseline.

Key Market Opportunities:

• Consistent Demand from Chronic Disease Prevalence: The global rise in hypertension and cardiovascular disease ensures a sustained and growing patient population requiring antihypertensive treatment. DIUPRES-500, as a widely recognized and affordable option, is well-positioned to benefit from this demographic trend. Global hypertension prevalence affects approximately 1.28 billion adults worldwide [5].
• Essential Medicine Status: Hydrochlorothiazide is often classified as an essential medicine by the World Health Organization (WHO). This designation ensures its inclusion in essential drug lists and procurement programs by governments and non-governmental organizations, guaranteeing a baseline level of demand, particularly in low- and middle-income countries.
• Fixed-Dose Combination (FDC) Products: The inclusion of hydrochlorothiazide in FDC products represents a significant opportunity. These combinations offer convenience and improved adherence for patients, often commanding higher ASPs than monotherapy generics. Manufacturers can leverage DIUPRES-500's established profile in developing and marketing new or existing FDC products. For example, the market for combination antihypertensives is substantial and growing.
• Emerging Market Expansion: Developing economies with increasing healthcare infrastructure and a growing middle class present a significant opportunity for affordable medications. DIUPRES-500's cost-effectiveness makes it an attractive option for these markets, where novel and expensive therapies may be inaccessible.
• Manufacturing Efficiency and Cost Leadership: For generic manufacturers, achieving superior manufacturing efficiency and cost control is a key competitive advantage. Companies that can produce high-quality hydrochlorothiazide at the lowest cost can capture substantial market share and generate consistent revenue, even at low unit prices.
• Supply Chain Reliability: In an environment where supply chain disruptions are a concern, a manufacturer that can demonstrate a robust, reliable, and transparent supply chain for DIUPRES-500 can build trust with payers and providers, securing consistent orders.

Key Takeaways

DIUPRES-500, a hydrochlorothiazide-based medication, operates in a mature, heavily genericized market. Its financial trajectory is characterized by stable, volume-driven revenue rather than high profit margins, a direct consequence of expired patents and intense competition. The drug's affordability and efficacy in treating hypertension and edema ensure consistent global demand. Key opportunities lie in its continued inclusion in fixed-dose combination therapies, expansion into emerging markets, and achieving cost leadership through manufacturing efficiency. However, challenges include persistent price erosion, limited differentiation for the branded product, and the ongoing regulatory landscape for generics.

Frequently Asked Questions

1. What is the current market share of the branded DIUPRES-500 compared to generic hydrochlorothiazide? The branded DIUPRES-500 likely holds a very small single-digit market share within the overall hydrochlorothiazide market. The vast majority of market share is attributed to generic hydrochlorothiazide products and fixed-dose combination therapies containing hydrochlorothiazide.

2. Are there any upcoming patent expirations that could impact the generic market for hydrochlorothiazide? No, the foundational patents for hydrochlorothiazide expired decades ago. The market is entirely based on generic competition, and no further patent expirations are relevant to the primary molecule.

3. What are the primary therapeutic indications for DIUPRES-500? DIUPRES-500 is indicated for the treatment of hypertension (high blood pressure) and edema (fluid retention) associated with conditions such as congestive heart failure, liver cirrhosis, and renal disease.

4. How does the pricing of DIUPRES-500 compare to its generic equivalents? The branded DIUPRES-500 would typically be priced higher than generic hydrochlorothiazide tablets. However, the price difference is often marginal, and the cost of generic hydrochlorothiazide is very low, generally ranging from \$0.05 to \$0.20 per tablet for the monotherapy.

5. What is the projected growth rate for the overall hydrochlorothiazide market? The overall hydrochlorothiazide market is projected for modest growth, with an estimated compound annual growth rate (CAGR) of around 4.5% through 2028, driven by increasing demand in emerging economies and the persistent prevalence of hypertension.

Citations

[1] Grand View Research. (2023). Hydrochlorothiazide Market Size, Share & Trends Analysis Report. [2] U.S. Food and Drug Administration. (n.d.). Approved ANDAs for Hydrochlorothiazide. Retrieved from FDA database. [3] IQVIA. (2023). National Prescription Drug Data Report. [4] Definitive Healthcare. (2023). Drug Pricing Data for Hydrochlorothiazide and Combination Products. [5] World Health Organization. (2021). Hypertension.